Common stock, par value $0.001 per share
- Symbol
- ONCY
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Oncolytics Biotech, Inc.
ONCYNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On September 28, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing certain updates and progress relating to the REO 033 colorectal cancer study.…
Company context
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
Current securities
Registered securities in this filing
Oncolytics Biotech Inc. · 8-K · Filed 2026-09-28
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On September 28, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing certain updates and progress relating to the REO 033 colorectal cancer study. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.